Group Says S. Korea Drug Regulator Gives Pfizer Favorable Treatment
This article was originally published in PharmAsia News
Executive Summary
South Korean drug makers and civic groups accuse Pfizer of being "too cozy" with the country's drug regulators, citing a case in which one of its products received favorable treatment. The U.S. firm's anti-cholesterol Lipitor (atorvastatin) earlier this month received favorable treatment during price-setting decisions by the Health Insurance Review and Assessment Service, based on an economic feasibility assessment of cholesterol drugs. A Korean coalition of civic health groups said HIRA changed its pricing standards to hand Pfizer a favor worth as much as $20.7 million. A Pfizer spokeswoman said the Lipitor price cap already had been "slashed" by 20 percent in September when generics became available. (Click here for more
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.